Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

TxCell S.A.. (2/22/17). "Press Release: TxCell Successfully Completes a €11 Million Capital Increase [Not for release directly or indirectly in the United States of America, Canada, Australia or Japan]". Valbonne.

Organisations Organisation TxCell S.A. (Euronext Paris: TXCL)
  Organisation 2 Bpifrance
  Group France (govt)
Products Product investment banking
  Product 2 cell therapy
Index term Index term TxCell–SEVERAL: investment, 201701–201702 capital increase €11.1m with 5.55m new shares with warrants at unit price of €2
Person Person Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for TxCell S.A. (Euronext Paris: TXCL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top